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Abstract
Background: Formation of blood vessels requires the concerted regulation of an unknown number of genes in a spatial-,
time- and dosage-dependent manner. Determining genes, which drive vascular maturation is crucial for the identification of
new therapeutic targets against pathological angiogenesis.
Methology/Principal Findings: We accessed global gene regulation throughout maturation of the chick chorio-allantoic
membrane (CAM), a highly vascularized tissue, using pan genomic microarrays. Seven percent of analyzed genes showed a
significant change in expression (.2-fold, FDR,5%) with a peak occurring from E7 to E10, when key morphogenetic and
angiogenic genes such as BMP4, SMO, HOXA3, EPAS1 and FGFR2 were upregulated, reflecting the state of an activated
endothelium. At later stages, a general decrease in gene expression occurs, including genes encoding mitotic factors or
angiogenic mediators such as CYR61, EPAS1, MDK and MYC. We identified putative human orthologs for 77% of significantly
regulated genes and determined endothelial cell enrichment for 20% of the orthologs in silico. Vascular expression of
several genes including ENC1, FSTL1, JAM2, LDB2, LIMS1, PARVB, PDE3A, PRCP, PTRF and ST6GAL1 was demonstrated by in
situ hybridization. Up to 9% of the CAM genes were also overexpressed in human organs with related functions, such as
placenta and lung or the thyroid. 21–66% of CAM genes enriched in endothelial cells were deregulated in several human
cancer types (P,.0001). Interfering with PARVB (encoding parvin, beta) function profoundly changed human endothelial
cell shape, motility and tubulogenesis, suggesting an important role of this gene in the angiogenic process.
Conclusions/Significance: Our study underlines the complexity of gene regulation in a highly vascularized organ during
development. We identified a restricted number of novel genes enriched in the endothelium of different species and
tissues, which may play crucial roles in normal and pathological angiogenesis.
Citation: Javerzat S, Franco M, Herbert J, Platonova N, Peille A-L, et al. (2009) Correlating Global Gene Regulation to Angiogenesis in the Developing Chick Extra-
Embryonic Vascular System. PLoS ONE 4(11): e7856. doi:10.1371/journal.pone.0007856
Editor: Vincent Laudet, Ecole Normale Supe ´rieure de Lyon, France
Received June 25, 2009; Accepted October 17, 2009; Published November 17, 2009
Copyright:  2009 Javerzat et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by the Agence Nationale de la Recherche, ANR-05-JCJC-0060 ‘‘Glioma model’’ (MH), la Ligue contre le Cancer, comites de
Dordogne et Landes (SJ) and by grants from the European Union (STROMA Consortium 2004–2007, LSHC-CT-2003-5032, to AB). The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: m.hagedorn@angio.u-bordeaux1.fr
. These authors contributed equally to this work.
Introduction
During development or tissue remodeling, growth of blood
vessels by sprouting and intussusception is essential for adaptation
to increasing needs of oxygen and nutrients. In pathological
conditions such as cancer, developmental genes are reactivated in
the endothelium, leading to de novo growth of blood vessel to supply
the tumor with nutrients [1,2]. Detailed knowledge about
differences and similarities of gene regulation during normal and
pathological angiogenesis is essential to design new drugs aiming at
specific modulation of blood vessel growth and function. Gene
expression profiles of vascular endothelial cells (ECs) have been
determined after isolation of ECs from specific organs or tumors,
based on the expression of known EC-markers or incorporation of
fluorescent dyes [3,4,5], after stimulation with angiogenesis
modulators [6], or after treatment with atorvastatin [7]. Further-
more, microarrays and serial analysis of gene expression (SAGE)
have been used to identify genes specific for normal and tumor
blood vessels [8,9], and recently, for freshly isolated endothelial
cells and lymphatic endothelial cells [10]. Substractive transcrip-
tomic analysis has recently led to the identification of 58 genes
specific for the microvasculature [11]. However, all the above-
mentioned studies need experimental manipulation of ECs at
some point prior analysis of gene expression (e.g. FACS sorting).
Furthermore, gene expression signatures have not yet been
associated with a particular form of angiogenesis (eg. sprouting
vs. intussusception). During vascular development, cell-to-cell
communications take place between ECs, pericytes, vascular
smooth muscle cells, epithelial cells or bone marrow-derived cells
[12]. These interactions influence gene expression in ECs.
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7856Separation of the endothelial compartment from the rest of the
organ might compromise EC gene expression patterns and
exclude important genes with angiomodulatory activities. Indeed,
factors produced by stroma cells in contact with capillaries play
important roles in the establishment, maintenance and branching
of the vasculature [13,14,15,16,17,18]. We took advantage of the
CAM as a unique, accessible vascularized organ, whose capillary
bed matures in well-defined steps [19,20,21,22,23,24] and
determined its transcriptome.
We provide evidence for EC-enrichment for a large number of
regulated genes and show that the majority of them are
deregulated in highly vascularized tumors such as glioblastoma.
Our data thus constitute a valuable resource to streamline further
research of candidate molecules susceptible to mediate angiogen-
esis in pathological conditions.
Results
Morphological and molecular characterization of CAM
development
Adaptation of the CAM vascular bed to increasing oxygen
needs of the embryo follows a stereotyped pattern of development.
Growth of the initial vascular plexus occurs mainly through
sprouting angiogenesis between E5 and E7, followed by a phase of
intussusceptive angiogenesis, and then the network expands
without further changes in complexity [21,22,23]. This is
accompanied by increasing endothelial cell proliferation, which
peaks around E10 and strongly decreases after E13 [19,20]. The
capillary network of the allantoic vesicle at E5 (hereafter also called
CAM) is clearly visible by biomicroscopy (Fig. 1 A). Sambucus nigra
lectin staining confirms an immature vasculature at E5 with few
pericytes and Prox-1 positive cells scattered throughout the tissue
(Fig. 1 B, C, G). Pericytes and lymphatic endothelial cells associate
with vascular structures during the following days, and an
organized vascular tree is established by day 14 (Fig. 1 D–F).
Density and ramification of the vascular plexus increase constantly
throughout CAM development (Fig. 1 G).
We compared global gene expression changes of the CAM
between E5, E7, E10 and E14 using the recently released
Affymetrix chicken GeneChips.
Significance Analysis of Microarrays (SAM) analysis identified
1252 probe sets which detect significant gene expression changes
throughout CAM development (.2-fold, FDR,5%). This
corresponds to 7% of the original filtered input data set (17778
probe sets). Two hundred and sixty probes represented genes
regulated between E5 and E7 (162 up, 98 down, ratio up/down:
1.65-fold). The period from E7 to E10 is a particular highly active
phase as reflected by the large number of upregulated genes (537
up, 26 down, ratio up/down: 20.65-fold). Between E10 and E14,
the ratio was inversed with 179 transcripts upregulated and 250
downregulated (ratio 0.71). Selected regulated genes with
established or potential roles in angiogenesis between indicated
stages are listed in tables 1–3 (for complete list of regulated genes,
see Supplementary table S1).
Early growth phase: E5 to E7
The early phase of the CAM is characterized by extensive
growth of the vascular network, essentially by means of sprouting
angiogenesis. Important genes controlling morphogenesis and
blood vessel formation in vertebrates were found upregulated.
These include critical transcription factors such as SOX17, HEY1,
KLF2, members of the semaphorin family like SEMA6D,
SEMA3C, and genes encoding for various proteins required for
endothelial cell function such as RAMP2, NOV, VWF, PECAM1
and MGP (Table 1). At the same time, the establishment of the
CAM lymphatic vascular system is reflected by the concerted
activation of major factors which positively drive lymphangiogen-
esis such as RELN, its receptor VLDLR, LYVE1 and FIGF and its
receptor FLT4. Interestingly, COL4A2, the gene encoding the
precursor of the endogenous angiogenesis inhibitor canstatin [25],
was also upregulated during this period. Other essential angio-
genic modulators such as RSPO3 and SFRP1 were negatively
regulated between E5 and E7.
Co-expression/regulation of angiogenic genes was further
evidenced on the signal level by a cluster analysis of significantly
regulated genes (Fig. 2). Numerous genes are co-expressed with
genes with established roles in angiogenesis (shown in red).
Between E5 and E7, we found the positive angiogenic and
lymphangiogenic regulator RAMP2 [26,27] co-regulated with
LYVE1, PECAM1, VWF, SEMA6D and genes, which have not
yet been described to play a role in blood vessel growth such as
IPMK (inositol polyphosphate multikinase).
To obtain general information about biological processes
enriched or activated between E5 and E7, we submitted all genes
regulated during this to the DAVID database. DAVID associates
Gene Ontology terms with a set of genes and calculates
enrichment compared to the rest of the genome. Cell adhesion
was found to be the predominant process, which associates 8
critical genes including ITGA1, ITGA6, RELN and LYVE1
(extracellular link domain containing 1) (Supplementary figure S2).
Cell-matrix interactions are of fundamental importance during
vascular development (for review see [28,29]). These results
suggest that the early developing CAM is especially active in
regard to matrix remodeling and adhesion.
Intermediate (E7 to E10) and late growth phase (E10 to
E14)
Between E7 and E10, the CAM vasculature undergoes active
remodeling associated with a high index of EC proliferation
[19,20]. This is reflected by the fact that very few genes were
downregulated during that period (Table 2 and Supplementary
table S1).
EPAS1 (hypoxia-inducible factor 2a) was significantly regulated
throughout the development and peaked around E10: 2.41-fold up
from E7 to E10 (qPCR: 2.65-fold), 0.38-fold down from E10 to
E14 (qPCR: 0.18-fold). Another essential angiogenesis modulator,
CYR61, declined together with EPAS1 from E10 to E14: 0.49-fold
(qPCR: 0.51-fold).
Interestingly, FIGF (encoding vascular endothelial growth factor
D) showed two peaks of regulation (3.92-fold up from E5 to E7,
down 0.23-fold from E7 to E10 and up 7.42-fold again from E10
to E14; Table 3). The most strongly downregulated gene (0.01-
fold) during that period was COL4A2, the gene encoding the
precursor for the angiogenesis inhibitor canstatin.
BMP4 was one of the highest upregulated genes between E7
and E10 and co-regulates with the gene encoding its high affinity
receptor, ACVR1 (activin A receptor, type I). In this cluster was
also an EC-expressed gene, MMRN1 (multimerin 1), which
encodes a large protein with a similar structure to von Willebrand
factor [30].
Interestingly, the Gene Ontology analysis found enrichment of
genes with known roles in morphogenesis and vascular develop-
ment (1.99-times) amongst the genes upregulated during the
period from E7 to E10. Again, this includes BMP4 and ACVR1,
together with SMO, HOXA3 and other morphogens (Supple-
mentary figure S2). This is likely correlated with an increasing
complexity of the CAM vasculature associated with increasing
differentiation of specific cell populations. Between E10 and E14, a
The CAM Transcriptome
PLoS ONE | www.plosone.org 2 November 2009 | Volume 4 | Issue 11 | e7856Figure 1. Morphological description of CAM development and gene regulation. A) By day 5 of development, the allantoic vesicle (arrows)
has emerged and contains a dense vascular network (biomicroscopy, 640). B, C) Immunofluorescence of CAM whole-mounts using markers for
endothelial cells (SNA lectin), pericytes (desmin) and lymphatic cells (Prox-1). At this stage, the capillary network appears unstructured; few pericytes
are associated with the vessels and single lymphatic endothelial cells are scattered throughout the tissue. D) By day 14, the CAM vasculature is
hierarchized, a clearly structured vascular tree has developed; feeder vessels (arrows) project into the two-dimensional capillary layer (asterisks;663).
E, F) Immunofluorescence analysis shows dense pericyte coverage of larger vessels and the existence of an organized lymphatic vascular network. G)
Evolution of the capillary network from E5 to E14. Note progressive densification of the capillary plexus from E5 to E7 by means of sprouting
angiogenesis; and from E7 to E10 increasingly by intussusceptive angiogenesis [97]. From E10 to E14, little morphological changes are observed in
the capillary layer, but some feeder vessels show more ramifications (bars: 200 mm). H) Gene expression analysis during CAM development and
Significant Analysis of Microarrays (SAM) identified 1252 probe sets regulated more than 2-fold during the compared periods. I) Ratios of up and
downregulated genes reveals a highly active growth phase between E7 and E10 (.20 times genes upregulated), followed by a shift to gene
downregulation from E10 to E14.
doi:10.1371/journal.pone.0007856.g001
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SNAI2. Not present in the Cluster, but also downregulated during
this period was TWIST1 (0.46-fold). These three genes are
functionally linked and are essential for normal blood (and
lymphatic) vessel formation in Xenopus laevis [31]. Gene ontology
analysis performed on the genes downregulated from E10 to E14,
identified ‘‘mitosis’’ as the most enriched biological process.
Numerous genes essential for coordinated cell proliferation
including CCNA2, CCNB2 and MAD2 are downregulated during
this phase, confirming that the CAM has entered a more quiescent
developmental stage.
Ortholog identification and in silico prediction of EC vs
Non-EC expression
To focus on genes, which may have conserved function between
vertebrates, we next applied three algorithms to identify human
orthologs of chicken genes. All genes significantly regulated at any stage
of CAM development were analyzed by an automated ortholog screen.
This procedure led to a more precise identification of previously
unannotated or poorly annotated chicken genes. At the time of analysis
(March 2009), our method assigned a high quality prediction for about
77.55% of the regulated genes (Supplementary table S2).
The CAM is a highly vascularized tissue and mainly contains
capillaries and larger vessels. ECs therefore constitute their
main cellular component, but epithelial cells and other stromal
cells (e.g. unclassified macrophages) are also present. We
determined whether any given ortholog regulated during
CAM maturation had preferential expression in endothelial
cells compared to non-endothelial cells using a recently
published in silico method, which compares sequence of any
given gene to two pools of EST cDNA libraries, endothelial
ESTs and non-endothelial ESTs, followed by an FDR-based
approach [32]. This analysis assigned EC-enrichment of more
than two-fold to 178 unique transcripts. Amongst the most EC-
specific genes were 35 transcripts with absolute EC-specificity
(e.g. no EST clones isolated from non-endothelial cells have
been reported), including JAM2, SOX7, SOX17, HEY1,
SEMA6D and UNC5B (Table 4 and Supplementary table
S3). Note that genes encoding proteins already used as
endothelial markers are identified using this approach and
d i s p l a yv e r yh i g hE C - e n r i c h m e n tr a t i o s( V W F :n on o n - E C
clones found; PECAM1: 179-fold enrichment). Accordingly, we
found 297 unique transcripts in the Non-EC pool, including
MDK, CALR and COL4A2 (Supplementary table S4).
Table 1. Selected regulated genes during the early phase of CAM development (E5 to E7).
Gene ID Fold Change Gene Symbol Gene Title
Gga.540.1.S1_at 8,49 MGP matrix Gla protein
Gga.19409.1.S1_at 6,33 COL4A2 collagen, type IV, alpha 2
Gga.496.1.S1_at 5,00 RELN reelin
Gga.2587.1.S1_at 4,82 NOV nephroblastoma overexpressed gene
GgaAffx.25229.1.S1_at 4,56 VWF von Willebrand factor
GgaAffx.3009.1.S1_s_at 4,01 SEMA6D Sema domain, transmembrane domain (TM), and cytoplasmic domain,
(semaphorin) 6D
Gga.3219.1.S1_at 3,92 FIGF c-fos induced growth factor (vascular endothelial growth factor D)
Gga.566.1.S1_at 3,74 ITGA1 integrin, alpha 1
Gga.4675.1.S2_at 3,53 SDC2 syndecan 2
Gga.7528.1.S1_at 3,52 KLF2 Kruppel-like factor 2 (lung)
Gga.19409.1.S1_s_at 3,14 COL4A2 collagen, type IV, alpha 2
Gga.1846.1.S2_at 3,12 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3C
Gga.12186.1.S1_at 3,11 LYVE1 lymphatic vessel endothelial hyaluronan receptor 1
Gga.1761.1.S1_at 2,99 GPR116 G protein-coupled receptor 116
Gga.6311.1.S1_at 2,97 HEY1 hairy/enhancer-of-split related with YRPW motif 1
Gga.2827.2.S1_a_at 2,91 TIMP3 TIMP metallopeptidase inhibitor 3 (Sorsby fundus dystrophy,
pseudoinflammatory)
Gga.7231.1.S1_at 2,42 SOX17 SRY (sex determining region Y)-box 17
GgaAffx.24123.1.S1_at 2,40 PDE3A phosphodiesterase 3A, cGMP-inhibited
Gga.679.1.S1_at 2,38 VLDLR very low density lipoprotein receptor
GgaAffx.25881.1.S1_at 2,34 PECAM1 platelet/endothelial cell adhesion molecule (CD31 antigen)
Gga.5541.1.S1_at 2,18 PECAM1 platelet/endothelial cell adhesion molecule
Gga.15805.1.S1_at 2,08 FLT4 fms-related tyrosine kinase 4
Gga.12104.1.S1_at 2,03 RAMP2 receptor (G protein-coupled) activity modifying protein 2
Gga.19305.1.S1_at 0,12 RSPO3 R-spondin 3 homolog (Xenopus laevis)
Gga.4830.1.S1_at 0,37 SFRP1 secreted frizzled-related protein 1
Gga.5170.1.S1_s_at 0,42 PODXL podocalyxin-like
A selection of relevant genes during the early period of CAM development are shown (for all significantly regulated genes, see Supplementary table S1). Downregulated
genes are in italic.
doi:10.1371/journal.pone.0007856.t001
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Endothelial expression of selected genes was further validated by
in situ hybridization inthe developing CAMatdifferentstages(Fig.3
A–E). Expression of CYR61 was found in CAM ECs of larger
conductvessels,stainingofcapillarieswaslesspronounced.Thiswas
also confirmed in sections of E4 chicken embryos, where strong
CYR61 signal was present in ECs of larger blood vessels (data not
shown). RAMP2 and EPAS1 showed intense expression in ECs of
the capillary layer and also in feeder vessels. SOX7 transcripts were
detected in ECs of E7 CAM and E4 chick embryonic vessels (Fig. 3
F). DAG1 (encoding dystroglycan) was strongly expressed in
epithelial cells adjacent to the capillary network, but not in ECs,
even though it has been shown that dystroglycan can be produced
by ECs and plays distinct roles in angiogenesis [33].
ENC1 marks liver blood vessels (arrows). JAM2 labels aortic
trunk (not shown) and inferior vena cava (arrows, H). PARVB,
LIMS1, PRCP, PTRF and FSTL1 were found in capillaries in
brain parenchyma, with a similar pattern as CDH5. LDB2
exhibits a staining similar to CD31 in lung and PODXL probes
label tongue capillaries. ST6GAL1 and PDE3A strongly mark
large blood vessels, such as the aorta (arrows).
Conserved gene expression between CAM and human
organs
Transcripts regulated during CAM maturation were compared
to sets of genes overexpressed in human tissues. The developing
CAM shared the highest number of genes with placenta (9.44%;
1.63-fold over the mean percentage of all organs together), followed
by the lung (8.05%, 1.39-fold) and the highly vascularized thyroid
(7.42%; 1.28-fold) (Table 5). All other organs had lower ratios, with
the skin being the organ with fewest common genes (3.82%). We
then determined to which extent EC-enriched genes regulated
during CAM development where also enriched in human organs.
Here again, placenta contained the highest number of shared genes
(28%; 1.54-fold over mean enrichment), followed by the thyroid
(26%, 1.44-fold) and the lung (20%; 1.13-fold). Skin and kidney
were the organs with lowest similarity to the CAM (12% each).
PECAM1, the gene encoding for the pan-endothelial marker
CD31, was found in all organs, except liver, pancreas and kidney.
PTPRF (protein tyrosine phosphatase, receptor type, F) also seems
to have broad endothelial expression, since it is expressed in
placenta,thyroid,lung,liverandbrain(Supplementary figure S3A).
CAM/Placenta and CAM/Lung-enriched genes showed a high
degree of overlap with 63 shared genes (Supplementary figure S3
B). This set of genes expressed in organs with oxygen-delivering
function contains critical factors such as CYR61, EPAS1, HES1,
HEY1, ID3, KLF2, SOX7, RAMP2 and TFEB, which are known
to play pivotal roles in vascular remodeling and morphogenesis.
More than half (57%) of the genes shared between CAM and
placenta and lung were also enriched in the thyroid (Supplemen-
tary figure S3 B). Interestingly, this set of genes also contained the
previously described endothelium-enriched gene GPR116 (G
protein-coupled receptor 116) [11] and C8orf4 (Thyroid cancer
protein 1), which may play a role in thyroid cancer progression
[34].
Table 2. Selected regulated genes during the intermediate phase of CAM development (E7 to E10).
Gene ID Fold Change Gene Symbol Gene Title
Gga.686.1.S1_at 8,40 BMP4 bone morphogenetic protein 4
GgaAffx.20323.1.S1_at 7,32 DAG1 dystroglycan
Gga.8140.1.S1_at 4,37 FGFBP1 fibroblast growth factor binding protein 1
Gga.1964.1.S1_at 3,55 MYO10 myosin X
Gga.4048.1.S1_at 3,49 ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein
Gga.2875.2.S1_a_at 3,34 ACVR1 activin A receptor, type I
Gga.889.1.S1_at 3,12 ITGA3 integrin, alpha 3 (antigen CD49C, alpha 3 subunit of VLA-3 receptor)
Gga.18461.1.S1_s_at 2,76 PTPRF protein tyrosine phosphatase, receptor type, F
Gga.4082.1.S1_at 2,67 SMO smoothened homolog (Drosophila)
Gga.496.1.S1_at 2,59 RELN reelin
Gga.11518.1.S1_at 2,58 — —
Gga.3381.1.S2_at 2,58 HOXA3 homeobox A3
Gga.1030.1.S1_at 2,57 MYC v-myc myelocytomatosis viral oncogene homolog (avian)
Gga.3673.1.S2_at 2,49 LDB2 LIM domain binding 2
Gga.3035.1.S1_at 2,41 EPAS1 endothelial PAS domain protein 1
GgaAffx.24545.1.S1_at 2,33 ENC1 ectodermal-neural cortex (with BTB-like domain)
GgaAffx.20877.1.S1_at 2,29 SOX7 SRY (sex determining region Y)-box 7
Gga.977.1.S1_at 2,25 PTRF polymerase I and transcript release factor
Gga.19289.1.S1_at 2,07 PRCP Prolylcarboxypeptidase (angiotensinase C)
GgaAffx.20978.1.S1_s_at 2,05 FGFR2 fibroblast growth factor receptor 2
Gga.9700.1.S1_at 2,05 TSPAN7 tetraspanin 7
Gga.19409.1.S1_at 0,01 COL4A2 collagen, type IV, alpha 2
Gga.3219.1.S1_at 0,23 FIGF c-fos induced growth factor (vascular endothelial growth factor D)
A selection of relevant genes during the intermediate period of CAM development are shown (for all significantly regulated genes, see Supplementary table S1).
Downregulated genes are in italic.
doi:10.1371/journal.pone.0007856.t002
The CAM Transcriptome
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malignancies
Genes with distinct functions in physiological angiogenesis are
often deregulated in pathologies such as cancer and may play
pivotal roles, thereby representing new therapeutic targets [35].
Using the Oncomine database [36], we determined the expression
status of EC-enriched genes regulated during CAM development
in four different cancer types which depend heavily on
angiogenesis and which are to a certain degree sensitive to anti-
angiogenic therapy. A large number of these genes were
deregulated, up to 66% in glioblastoma, 34% in lung adenocar-
cinoma, 27% in colon carcinoma and 21% in renal cell carcinoma
(Figure 4 A). Importantly, PRCP, PTRF, LIMS1 and FSTL1 were
expressed in the developing murine brain vasculature (see Figure 3
M, O, P, Q) and are also overexpressed in glioblastoma (Figure 4
B), suggesting a role in tumor angiogenesis. As expected, VEGF
was strongly overexpressed in glioblastoma samples, whereas
RGS4 (regulator of G-protein signaling 4) [37], a negative
regulator of VEGF-signaling, was downregulated.
Effects of PARVB knock down in human EC cells
We then explored functional implication of one of the CAM
genes, PARVB, in the angiogenic process. We first determined
efficacy of the PARVB siRNA in hCMEC/D3 endothelial cells.
Target transcripts were potently reduced by more than 90% over a
period up to 96h. transfected with PARVB siRNA showed
profound changes in morphology as early as 3h after plating on
collagen or fibronectin (Figure 5A, B). Cells transfected with non
targeting siRNA (siCT) showed no morphological difference
compared to untreated cells (data not shown). siPARVB cells
appeared rounder and more spread-out compared to control cells.
The culture dish area covered by a same number of cells was 2-
fold for siPARVB (P,.0001) (Figure 5G). This phenomenon was
observed after three hours, but not restricted to the initial
adhesion, as siPARVB cells stayed larger over time, up to 72h
(Figure 5E). The round phenotype of siPARVB cells is
accompanied by a rearrangement of the actin cytoskleton as
evidenced by rhodamine-phalloidin staining (Figure 5C, D). Actin
fibers concentrate at the cell border and are orientated in a
circular manner at the periphery.
We then challenged siPARVB cells in several functional tests to
verify if the morphological changes affect cell motility. As seen in
Figure 5H, short-term (3h) EC migration through transwell filters
in response to serum was significantly reduced compared to
controls (approx. 2-fold reduction). In an invasion assay, where
cells have to migrate through Matrigel, a 3.7-fold reduction of
siPARVB cells was evidenced (P,.0001). On the other hand,
PARVB knock down had no significant effect on cell proliferation
at any time point tested (Figure 5J). Endothelial cells dispersed in
matrigel assemble into tube-like structures if stimulated by serum
or growth factors (tubulogenesis assay). siPARVB cells had
Table 3. Selected regulated genes during the late phase of CAM development (E10 to E14).
Gene ID Fold Change Gene Symbol Gene Title
Gga.19409.1.S1_at 89,38 COL4A2 collagen, type IV, alpha 2
Gga.3219.1.S1_at 7,42 FIGF c-fos induced growth factor (vascular endothelial growth factor D)
Gga.5334.1.S1_a_at 2,66 RGS4 regulator of G-protein signaling 4
GgaAffx.12606.1.S1_s_at 2,56 JAM2 junctional adhesion molecule 2
GgaAffx.22422.1.S1_s_at 2,20 AMOT angiomotin
Gga.977.1.S1_at 2,09 PTRF polymerase I and transcript release factor
Gga.16689.1.S1_s_at 0,18 PARVB parvin, beta
Gga.805.2.S1_a_at 0,30 EPHA3 EPH receptor A3
Gga.1964.1.S1_at 0,30 MYO10 myosin X
Gga.5002.1.S1_at 0,32 MDK midkine (neurite growth-promoting factor 2)
GgaAffx.20323.1.S1_at 0,33 DAG1 dystroglycan
GgaAffx.1193.1.S1_s_at 0,33 LAMA1 laminin, alpha 1
Gga.3035.1.S1_at 0,38 EPAS1 endothelial PAS domain protein 1
Gga.1846.1.S1_at 0,42 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3C
Gga.18504.1.S1_at 0,43 PARVA parvin, alpha
Gga.3973.1.S1_at 0,44 TWIST1 twist homolog 1 (Drosophila)
Gga.5109.1.S1_s_at 0,46 MYCN v-myc myelocytomatosis viral related oncogene, neuroblastoma derived
(avian)
Gga.2200.1.S1_at 0,49 CYR61 cysteine-rich, angiogenic inducer, 61
Gga.19934.1.S1_at 0,49 SNAI2 snail homolog 2 (Drosophila)
Gga.1846.1.S2_at 0,49 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted,
(semaphorin) 3C
Gga.2679.2.S1_a_at 0,49 FBLN1 fibulin 1
GgaAffx.21814.1.S1_s_at 0,50 LIMS1 /// LOC771176 LIM and senescent cell antigen-like domains 1 /// hypothetical protein
LOC771176
A selection of relevant genes during the late period of CAM development are shown (for all significantly regulated genes, see Supplementary table S1). Downregulated
genes are in italic.
doi:10.1371/journal.pone.0007856.t003
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PLoS ONE | www.plosone.org 6 November 2009 | Volume 4 | Issue 11 | e7856Figure 2. Co-expression of established and potential regulators of angiogenesis during CAM maturation. Cluster analysis of expression
values of all probe sets representing significantly regulated genes between indicated periods. For each indicated period, the left cluster shows all
probe sets, the right shows the transcripts of the node indicated by a black bar. The nodes correspond to transcripts co-expressed with genes known
to control vascular morphogenesis (gene symbol in red). In blue are co-expressed genes with established function in the same process (e.g.
lymphangiogenesis: RAMP2 and LYVE1), which physically interact (BMP4 and ACVR1) or which participate in the same signaling chain (MYCN, SNAI2).
Arrows indicate genes enriched in endothelial cells (data from Supplementary table S3).
doi:10.1371/journal.pone.0007856.g002
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the gel which have not made contacts with other cells. Tubes
themselves appeared thinner than controls (Figure 5 F).
Discussion
In this study, we took advantage of the chick CAM as a unique
vascular organ accessible for gene expression studies without any
experimental manipulation of the tissue prior to mRNA isolation
to identify new potential regulators of angiogenesis. Most cellular
components of the CAM are either blood vessels and capillaries or
epithelial cells in direct contact to capillaries. This makes the CAM
an attractive model tissue to investigate gene regulation and
expression throughout vascular development in vivo. We used
cluster analysis, human ortholog screening, endothelial cell EST-
to-gene assignments [32] and comparison with genes overex-
pressed in human tissues and tumors to focus on genes of possible
relevance to human pathologies.
Key modulators of angiogenesis are regulated during
CAM maturation
It has been shown previously, that EC proliferation in the CAM
peaks around day 10, then diminishes strongly [19,20]. This active
state of the endothelium is reflected by our study, with nearly 20-
times more genes upregulated from E7 to E10, followed by a
decrease in transcriptional activity after E10. Moreover, from E10
to E14, gene ontology analysis using DAVID [38,39] found
Table 4. Endothelial enrichment of putative human orthologs of CAM genes.
Significant regulation period Gene Human product EC-specific expression (q-value) EC/Non-EC ratio
Up E10 to E14 JAM2 junctional adhesion molecule 2 0 —
Up E7 to E10 MMRN1 multimerin 1 0 —
Up E7 to E10 SOX7 SRY (sex determining region Y)-box 7 0 —
Up E5 to E7 VWF von Willebrand factor 0 —
Up E5 to E7 HEY1 hairy/enhancer-of-split related with YRPW motif 1 0.01 —
Up E5 to E7 C8orf4 chromosome 8 open reading frame 4 0.1 —
Up E10 to E14 GPR137B G protein-coupled receptor 137B 0.1 —
Up E5 to E7 SOX17 SRY (sex determining region Y)-box 17 0.1 —
Down E7 to E10 CENPL centromere protein L 0.29 —
Down E10 to E14 DISP1 dispatched homolog 1 (Drosophila) 0.29 —
Down E10 to E14 DTL denticleless homolog (Drosophila) 0.29 —
Up E7 to E10 MXD1 MAX dimerization protein 1 0.29 —
Up E5 to E7 PDE3A phosphodiesterase 3A, cGMP-inhibited 0.29 —
Up E5 to E7 SEMA6D sema domain, transmembrane domain (TM), and
cytoplasmic domain, (semaphorin) 6D
0.29 —
Up E7 to E10 SHE Src homology 2 domain containing E 0.29 —
Up E7 to E10 UNC5B unc-5 homolog B (C. elegans) 0.29 —
Down E10 to E14 A2M alpha-2-macroglobulin 0 208.91
Up E5 to E7 PECAM1 platelet/endothelial cell adhesion molecule 0 179.00
Up E7 to E10 ARSJ arylsulfatase family, member J 0.01 23.00
Up E10 to E14 RGS4 regulator of G-protein signaling 4 0 20.23
Up E5 to E7 EMP1 epithelial membrane protein 1 0 19.87
Up E7 to E10 PRCP prolylcarboxypeptidase (angiotensinase C) 0 17.52
Up E7 to E10 EFEMP1 EGF-containing fibulin-like extracellular matrix protein 1 0 15.91
Down E5 to E7 TTK TTK protein kinase 0.12 13.71
Down E5 to E7 PODXL podocalyxin-like 0 13.14
Down E10 to E14 WDSOF1 WD repeats and SOF1 domain containing 0.01 12.87
Up E7 to E10 PTRF polymerase I and transcript release factor 0 12.65
Up E7 to E10 LDB2 LIM domain binding 2 0 8.68
Up E5 to E7 ITGA6 integrin, alpha 6 0.01 6.95
Down E10 to E14 PARVB parvin, beta 0.05 6.66
Up E7 to E10 MYC v-myc myelocytomatosis viral oncogene homolog (avian) 0.03 6.08
Down E10 to E14 CYR61 cysteine-rich, angiogenic inducer, 61 0 6.01
Up E7 to E10 TSPAN7 tetraspanin 7 0.18 5.86
A selection of CAM development genes with high EC-enrichment (.5). Not that numerous genes (including JAM2, SOX7, VWF, PECAM1 and UNC5B) had absolute EC
specificity (zero non-EC EST assignments). Genes with validated EC expression by in situ hybridization are marked in bold (complete list of EC-enriched genes are in
Supplementary table S3).
doi:10.1371/journal.pone.0007856.t004
The CAM Transcriptome
PLoS ONE | www.plosone.org 8 November 2009 | Volume 4 | Issue 11 | e7856Figure 3. In situ hybridization of CAM development genes. A–F) Specific expression of indicated genes in the chick embryo (CAM: A–E; E4
embryo: F). CYR61, RAMP2, EPAS1 and SOX7 are expressed by ECs of the CAM (arrows). C) DAG1 is strongly expressed in epithelial cells adjacent to
the capillary network of the CAM (arrow). F) SOX7 transcripts were also found in E4 embryonic vessels (arrows); (epi=Epithelium, ca=capillary
network, bv=blood vessel. A–C: scale bar=100 mm, D–F, scale bar=50 mm; A+C: E7, B: E10; D: E10). G–T) Blood vessels of different origin positive for
indicated transcripts in mouse E14.5 embryos (sagittal sections). G) ENC1 marks liver blood vessels (arrows) and JAM2 labels inferior vena cava
(arrows, H). Highly endothelial-specific CDH5 (VE-Cadherin) and PECAM1 (CD31) served as positive controls to demonstrate morphological
appearances of micro- and macrovascular structures. Insert in I shows a typical brain capillary at higher magnification. PARVB, LIMS1, PRCP, PTRF,
FSTL1 were found in capillaries in brain parenchyma (L, M, O, P, Q), with a pattern comparable to CDH5 (I). LDB2 exhibits a staining similar to CD31 in
lung (N), and PODXL probes label tongue capillaries (K). ST6GAL1 and PDE3A strongly mark large blood vessels, such as the aorta (arrows),
comparable to the known marker PECAM1 (CD31). All images were taken at digital zoom levels, which best demonstrated vascular patterns (www.
genepaint.org).
doi:10.1371/journal.pone.0007856.g003
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ulated genes. On the other hand, from E7 to E10, genes were
enriched that control blood vessel growth and morphogenesis,
including BMP4, ACVR1, SMO and HOXA3. Interestingly, it
has been suggested recently that HOXA3 expression provides
positional cues during the development of the vasculature [40].
This study also validated endothelial HOXA3 protein expression,
as predicted by our in silico analysis.
In vertebrates, vascular development is controlled by the
hypoxia-inducible transcription factor EPAS1 [41,42]. EPAS1
was significantly regulated during CAM development, reflecting
the proliferation state of CAM ECs (e.g. upregulation from E7 to
E10, followed by downregulation) and was strongly expressed in
ECs, suggesting an active role of EPAS1 for CAM vascular
development. Another gene selectively expressed in larger CAM
vessels and whose regulation parallels EPAS1 from E10 to E14 is
CYR61, which might have a role for vascular development in the
CAM. A critical role in blood vessel development for this molecule
has been demonstrated in CYR61 null mouse embryos, which are
not viable because of severe vascular defects in the placenta [43].
Despite the fact that VEGF regulation did not reach
significance in the SAM analysis, standard Affymetrix fold-change
comparison showed a decrease of VEGF transcript levels by 50%
from E10 to E14 (data not shown). This correlates well with the
decrease in EC proliferation during this period.
FIGF, the gene for vascular endothelial growth factor D [44],
exhibited a bi-phasic regulation pattern, with peaks at E7 and at
E14. VEGF-D is strongly expressed in the mouse lung, promotes
lymph- and hemangiogenesis, and is required for normal blood
vessel formation in the zebrafish [45,46]. It is possible that the first
peak of FIGF regulation reflects initiation of lymphangiogenesis
from E5 on. Noteworthy, from E5 to E7, FIGF is coregulated with
its receptor FLT4. Downregulation of FIGF from E7 to E10 and
then again upregulation to E14 - which is inverse to angiogenesis
stimulation - suggests that VEGF-D mainly acts on the lymphatic
system in the CAM or that its biological activity is controlled at the
post-transcriptional level. It is known that processing of VEGF-D
through cleavage occurs in the embryonic mouse lung, a step that
greatly enhances its affinity for its receptors KDR and FLT4 [47].
Noteworthy, COL4A2, the precursor for the angiogenesis
inhibitor canstatin [25], had the same regulation pattern as FIGF,
and both genes are amongst the transcripts, which exhibit the
highest fold-changes during CAM development. Co-expression of
angiogenesis inhibitors and stimulators fits well in the concept of
an angiogenic balance, where the effects of pro-angiogenic
molecules are restricted by inhibitors [48].
Other critical genes, which control vascular morphogenesis,
show significant regulation in our model. SDC2 (syndecan 2)
knock-down in the zebrafish leads to defects in sprouting
angiogenesis [49]. SDC2 is upregulated until E10 during CAM
development, covering thus the whole period when sprouting
angiogenesis occurs. UNC5B, also upregulated during the most
active growth phase of the CAM, is expressed in ECs and its
interaction with its ligand netrin-1 (encoded by NTN1) is essential
for correct branching of the vasculature in mice and zebrafish
[50].
Novel genes with a functional role during vascular
development
During the preparation of this manuscript, several other genes
regulated between different stages of CAM maturation have been
proven essential for normal vascular development in other species.
In the early phase of the CAM, RSPO3 [51,52] decreases 0.12-
fold from E5 to E7, suggesting an important role of this factor at
the early stages of the development of the CAM, even before E5,
during the growth of the allantoic vesicle. Knockout of Rspo3
causes defects in the remodeling and establishment of placental
and yolk sac vasculature in mice, leading to embryonic death
around E10 [51,52]. Speculative at this point, decreasing levels of
RSP03 may reflect the switching from sprouting to intussusceptive
angiogenesis in the developing CAM vasculature [21].
Kru ¨ppel-like transcription factors play important roles during
development of the vascular system. KLF2 was upregulated
between E5 and E7 of development, a period of active vascular
expansion and recruitment of pericytes. KLF2 is not required for
the development of a vascular plexus, but a failure in smooth
muscle cell migration is observed in KLF null embryos, causing
vascular defects, which lead to bleeding and lethality [18].
Interestingly, another Kru ¨ppel-like factor, KLF5 is also required
for VSMCs recruitment during development and intima regener-
ation [53,54].
RAMP2 was found expressed in ECs of the CAM. It is a co-
receptor for adrenomedullin and is essential for developmental
Table 5. CAM development genes overexpressed in human organs.
Organ
Enriched unique
transcripts
Shared with unique
transcripts from CAM %
Fold over
Mean
Shared with unique EC-specific
transcripts from CAM %
Fold over
Mean
Placenta 1250 118 9.44 1.63 33 28 1.54
Lung 1702 137 8.05 1.39 28 20 1.13
Thyroid 1443 107 7.42 1.28 28 26 1.44
Kidney 906 50 5.52 0.95 6 12 0.66
Pancreas 943 46 4.88 0.84 8 17 0.96
Blood 1862 83 4.46 0.77 14 17 0.93
Brain 1364 60 4.40 0.76 9 15 0.83
Liver 1725 70 4.06 0.70 11 16 0.87
Skin 889 34 3.82 0.66 4 12 0.65
Mean 5.78 18
Comparison of human ortholog genes regulated during CAM development with genes overexpressed in indicated tissues. The highest percentage of common genes is
found in organs functionally related to the CAM such as placenta and lung, but also in the highly vascularized thyroid. When only EC-enriched CAM genes were
compared to the genes common between CAM and indicated organs, up to 28% of the genes were in common (for a list of these genes, see Supplementary figure S3).
doi:10.1371/journal.pone.0007856.t005
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PLoS ONE | www.plosone.org 10 November 2009 | Volume 4 | Issue 11 | e7856Figure 4. Overexpression of EC-enriched CAM genes in human cancers. A) Expression values of all genes with .2-fold EC enrichment were
retrieved for glioblastoma, lung adenocarcinoma, colon carcinoma and clear cell renal carcinoma samples using Oncomine. 66% of these genes were
found deregulated (over- and underexpression) in glioblastoma, 34% in lung adenocarcinoma, 27% in colon carcinoma and 21% in renal cancer,
compared to normal non-malignant tissue. B) Detailed expression profiles for selected genes in glioblastoma. Red=overexpression, green=under
expression; P,.0001 for all.
doi:10.1371/journal.pone.0007856.g004
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PLoS ONE | www.plosone.org 11 November 2009 | Volume 4 | Issue 11 | e7856Figure 5. PARVB knock down in hCEMC/D3 ECs. A–E, G) Morphological changes during cell adhesion in siPARVB transfected cells. Increased cell
size in the siPARVB treated cells can be observed as early as 3h after plating on fibronectin (FN; A) or collagen (COL; B), and differs significantly from
control cells; G). C, D) Staining of the actin cytoskleton with rhodamine-phalloidin (206). D) At higher magnification (D), note cytoskleton
rearrangement with circular orientation and concentration of actin bundles at the cell borders. E) Altered EC morphology persists over time, up to
72h. H, I). Quantitative analysis shows that PARVB knock down leads to approximately two-fold decrease in cell migration compared to control
(P,.0001) and 3.7-fold decrease in invasion through matrigel. J) Cell proliferation is not affected by PARVB knock down. F) Tubulogenesis is impaired
by PARVB knock down. Cells stay isolated and tube-like structures are poorly organized (magnification 46; all bars: 50mm).
doi:10.1371/journal.pone.0007856.g005
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specific expression of RAMP2 in the CAM capillaries as well as
larger vessels suggests a functional role of this molecule in CAM
development.
SOX7 is expressed in the developing Xenopus vasculature [55]
and ECs in the CAM and recent functional studies in zebrafish
revealed a redundant, yet essential role for SOX7 together with
the related SOX18 in vascular development [56,57,58].
Genes of a same functional network may be co-regulated during
vascular maturation. Myc null mice die around E10.5 due to
major defects in the developing vasculature [59]. SNAI2 and
TWIST1, two recently discovered downstream mediators of MYC
activity on vascular development in Xenopus laevis [31], are
downregulated together with MYC after E10 of CAM develop-
ment, underlining the importance of this regulatory circuit.
Interestingly, SNAI2 is strongly expressed in pericytes during
chick development [60].
CAM genes in human tissues
The CAM is the central oxygen-exchanging organ for the
developing chick embryo; its function thus shares features with
organs like the placenta and the lung. We therefore compared
genes regulated in the CAM to sets of genes overexpressed in
human tissues, including placenta and lung [61]. A set of 63
human orthologs is conserved between lung, placenta and the
CAM. This set of genes contained transcription factors which
control lung and/or placenta morphogenesis and vascularization
such as EPAS1 [41], HEY1 [62], and other critical genes such as
CYR61 and RAMP2 which also may play roles in placenta
pathology [63,64]. Interestingly, 34% of the genes shared between
the CAM and the thyroid, are also found in the CAM/placenta/
lung expressed genes. Even though the thyroid is functionally not
related to placenta or lung, it is a highly vascularized organ and
therefore may contain more EC transcripts than other tissues.
Two other transcriptomic studies of ECs isolated from mouse
lungs and other tissues [5,11] have identified numerous genes
enriched in the endothelial compartment. When intersected with
EC-enriched genes of the CAM transcriptome (Supplementary
table S3), only very few genes are found in common (2.8% for each
study). These genes are HEY1, ITGA6, PECAM1, TNFSF10 and
TSPAN7 (from the Favre study [5]) and EPAS1, GPR116,
PTPRM, SOX7 and TNFSF10 (from the Wallgard study [11]).
When the Favre and Wallgard studies are compared, 13.7% of the
reported genes are common (data not shown).
The reason for this low overlap might lie in the different
methods used to isolate mRNA, and the different filters that we
specifically applied. We introduced a dynamic parameter, e.g.
regulation between two time points, which obviously eliminates
genes that are constantly expressed by the endothelium. Also, we
included only genes with human orthologs, which limits
comparison with mouse genes. Last, we restricted our analysis to
genes enriched in endothelial ESTs libraries. Various, comple-
mentary approaches are still needed to identify possible future
candidates critical for vascular development.
New potential regulators
The fact that a large number of essential modulators of
angiogenesis participate in CAM vascular development suggests
that genes previously not associated with blood vessel formation
might be present in the gene signatures we have described. For
example, class 3 semaphorins, such as SEMA3A and –F, which are
secreted neuronal guidance proteins, are also negatively regulating
blood vessel branching [65]. SEMA3C, which is associated with
CAM vascular maturation, has not been investigated in vivo,
although it stimulates EC proliferation and survival in vitro [66].
PTRF displays a high EC-enrichment (.12-fold) and is
expressed in brain capillaries. It encodes a protein found in
caveolae and is essential for their function [67]. Caveolae are
central structural components of ECs and control cell behavior
and signaling [68]. Furthermore, PTRF was found overexpressed
in glioblastoma.
PARVB, encodes beta-parvin, which negatively regulates
integrin-linked kinase (ILK) activity in breast cancer cells [69].
Integrin-linked kinase activity in the endothelium or in tumor cells
is essential for physiological and pathological angiogenesis
[70,71,72]. Therefore, PARVB expression in ECs suggests the
existence of a negative feedback loop on integrin-linked kinase
activity, which may be important during vascular development.
Since no direct data exist about the role of PARVB in
angiogenesis, we investigated the effects of PARVB knock down
in human immortalized capillary endothelial cells [73]. PARVB
depletion alters EC adhesion, migration, invasion and tubulogen-
esis, suggesting that Beta-parvin may play a role in modulating
angiogenesis.
It seems that Beta-parvin activity needs to be tightly controlled,
since overexpression of a ILK- phosphorylated COOH-terminal
fragment of Beta-parvin, blocks cell spreading of CHO cells at the
initial stage [74]. Another domain of Beta-parvin, which interacts
with alpha-actinin, is also implicated in cell adhesion and loss/
gain-of-function experiments have shown deleterious effects on cell
adhesion [75]. Whether effects of PARVB knock down in ECs is a
direct or indirect effect mediated by deregulated integrin-linked
kinase activity remains speculative at this point. Interestingly, both
PARVA and PARVB are down-regulated during the later phase of
the CAM, when the endothelium becomes quiescent, suggesting
an implication of these two genes earlier in CAM angiogenesis.
Another gene with high EC-specificity is PODXL (podocalyxin-
like). However, PODXL, highly homologous to CD34, seems to
have redundant roles in vascular development, since Pdxl (2/2)
mice show no vascular abnormalities [76]. PODXL is nonetheless
significantly overexpressed in glioblastoma, suggesting a possible
implication in tumor angiogenesis.
Some attractive gene candidates identified in this study are
expressed elsewhere than in ECs. We found transcripts for
dystroglycan (DAG1) in the chorionic epithelium, which is in
close contact with the capillary network. Dystroglycan may
modulate angiogenesis via interaction with the alpha chain of
laminin-1, the gene product of LAMA1, which is downregulated
with DAG1 from E10 to E14 [33,77]). Based on our bioinformatic
analysis, several genes preferentially expressed in stromal cells may
play critical roles in CAM vascular maturation (see Supplementary
table S4). An interesting candidate is MDK encoding for Midkine,
a heparin-binding growth factor. Epithelial-expressed Midkine
controls lung vascular morphogenesis via upregulation of genes
critical for vascular smooth muscle cell function in a HIF-1alpha-
dependent manner [13]. Stromal cells might also restrict vascular
growth by producing precursor proteins for angiogenesis inhibi-
tors. We found genes encoding calreticulin (CALR) as well as
collagen 4A2 (COL4A2) enriched in the stromal compartement of
the CAM. Vasostatin, [78] a fragment of calreticulin and
canstatin, derived from the alpha2 chain of type IV collagen
[25] might negatively control vascular growth in the developing
CAM and perhaps restrict excessive angiogenesis. Interestingly,
COL4A2 is the most down regulated gene during CAM
angiogenesis from E7 to E10, when most genes are upregulated.
Importantly, some of the CAM development genes over
expressed in ECs might be markers of poor prognosis in human
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expressed in glioblastoma samples. Importantly, a recent study
confirmed association of FSLT1 over expression with poor
prognosis in glioblastoma patients [79]. FSTL1 is down regulated
after E10 in the CAM, at a time point when angiogenesis in the
CAM declines. FSTL1 might exert pro-angiogenic effects
(survival, migration) during development and tumor angiogenesis
in a similar manner as has been shown in vitro and in ischemic
tissue [80]. The exact role of other vascular genes such as PRCP,
LIMS1 and ENC1 in glioblastoma is not clear yet, but given their
expression pattern, an implication in tumor angiogenesis is
possible and merits further investigation.
Other genes, which are significantly regulated during CAM
development, play also central roles in human diseases with
vascular anomalies. TIMP3 mutations cause Sorby’s fundus
dystrophy, a disease, where choroidal vessel integrity is affected;
SOX18 inactivation leads to lymphedema-distichiasis syndrome,
with clinical signs of edema and abnormal morphology of
capillaries and arterioles and FLT4 mutations cause Nonne-
Milroy lymphedema (for review see [81]).
Conclusions
Taken together, the CAM transcriptome constitutes the first
detailed in vivo analysis of a vascular tissue during its maturation.
Our data show that the development of the vasculature in the CAM
of the chick embryo involves regulation of critical genes, which have
been reported to control vascular morphogenesis in far more
complex tissues, such as placenta and lung and which also show
deregulation in various human cancers, suggesting that these new
genes are involved in human pathologies in which vascular growth
and remodeling plays a central role (e.g. tumor angiogenesis).
Materials and Methods
Analysis of CAM development by biomicroscopy and
immunhistochemistry
The evolution of the CAM vascular network was visualized
from E5 to E14 by standard biomicroscopy at 10–636
magnifications. Immunhistochemistry of CAM whole mounts
was performed as described previously [82]. Lymphatic endothe-
lial cells were identified using a rabbit anti-Prox-1 antibody
(ab11941, 1:500, Abcam, Paris, France) and pericytes were
visualized with a rabbit anti-desmin (clone D33, 1:500, Dako,
Treppes Cedex, France). Corresponding secondary antibodies
were coupled to Alexa Fluor 546 (1:2000, Invitrogen, Cergy
Pontoise Cedex, France).
Isolation of CAM tissue for gene profiling
The developmental stage of the embryos was determined after
isolation of the CAM according to Hamburger & Hamilton (HH)
[83], and only CAMs from typical embryos were used. CAMs
were isolated from embryos at developmental day E5 (HH26), E7
(HH30), E10 (HH.35) and E14 (HH40), and directly snap-frozen
in liquid nitrogen mRNA was isolated using RNeasy minikit
(Qiagen, Courtaboeuf cedex, France) and hybridized to Affyme-
trix chicken GeneChips using the manufacturer’s standard
protocol (Affymetrix UK Ltd, High Wycombe, UK).
Affymetrix chicken GeneChips: comparison set-up and
statistical analysis
The chicken GeneChip covers 32773 transcripts corresponding
to .28000 chicken genes, has a probe set oligonucleotide length of
25 and a detection sensitivity of 1:100000 (http://www.affymetrix.
com). Data were analyzed with the GCOS 1.2 software
(Affymetrix), using the default analysis settings and global scaling
as first normalization method, with a trimmed mean target
intensity value (TGT) of each array arbitrarily set to 100.
Three individual CAMs of a same developmental stage were
compared to three CAMs from a more advanced stage. The raw
data set was filtered prior to further statistical analysis using the
following criteria: each probe set had to be labeled as ‘‘present’’ (P-
value,.04, Wilcoxon rank sum test) in all three embryos on at
least one developmental day. This set of 17778 probe sets was
subjected to Significance Analysis of Microarrays (SAM) analysis
[84] (http://www-stat.stanford.edu/,tibs/SAM/, which utilizes a
Wilcoxon-test statistic and sample-label permutation to evaluate
statistical significance between sample groups. SAM provides
mean fold change values (FC) (mean fold-change .2) and a false
discovery rate (FDR) confidence percentage based on data
permutation (n=200). The False Discovery Rate (FDR), an
estimate of the fraction of selective genes, was kept below 5% in all
statistical analyses (the graphical representation of the SAM
analysis is shown in Supplementary figure S1). Annotation of genes
was performed using NetAffx (http://www.affymetrix.com; March
2009). The 12 microarray data files have been submitted to the US
National Center for Biotechnology Information, Gene Expression
Omnibus (GEO), and will be released upon publication (approved
accession number: GSE11636; sample numbers: GSM294982,
GSM294983, GSM294984, GSM294985, GSM294986, GSM-
294987, GSM294988, GSM294989, GSM294990, GSM294991,
GSM294992, GSM294993).
Cluster analysis
To visualize expression values of genes identified as being
significantly regulated by the SAM analysis, we performed a
Cluster analysis between E5 and E7, E7 and E10 and E10 and
E14 (Cluster 3 for Mac OSX). Original hybridization signal data
were log transformed and median centered prior clustering
(hierarchical cluster for genes, correlation uncentered with average
linkage). The cluster was visualized (Java TreeView, Version
1.0.13) and genes known to control vascular morphogenesis were
searched. The aim was to evidence co-expression of genes
implicated in the same functional network or process or which
physically interact. Neighboring genes were displayed by selecting
the node close to the gene of interest (in red), co-expressed
angiogenesis genes were labeled in blue and genes with EC-
enrichment (from Supplementary table S3) indicated by an arrow.
Gene Ontology analysis
To get insight into the biological processes associated with the
regulated genes between the different periods, Affymetrix IDs were
submitted to the DAVID (Database for Annotation, Visualization
and Integrated Discovery) analysis tool [38,39]. We submitted all
probes upregulated from E5 to E7, from E7 to E10 (maximal
growth phase) and all probes downregulated from E10 to 14 (period
in which the CAM vasculature gets quiescent) and performed
functional annotation clustering, searching for biological processes,
which were enriched in our gene sets compared to the rest of the
chicken genome. All results are ranked based on a FDR-based q-
value and P-value (from a modified Fisher Exact test) and processes
(Gene Ontology ‘‘Biological Process’’ category) with the highest
enrichment were selected (for more information about DAVID,
please visit http://david.abcc.ncifcrf.gov/home.jsp).
Semi-quantitative real-time PCR
Total RNA was purified from pools of 10 CAMs per
developmental day using RNeasy columns (Qiagen, Courtaboeuf
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II RNase H- Reverse Transcriptase (Invitrogen, Cergy Pontoise
Cedex, France) by using oligo (dT)15 priming. Chicken-specific
primers for qPCR were designed and evaluated for amplification
efficiency. Primer sequences were: HNRPH1, 59- GCTGTG-
TCTGCCACGAGTTA -39,5 9- GCTTTCGGCTGAGAGA-
CAAT-39, EPAS1, 59- AATCCACCTGTGGCAGTCCT-39,5 9-
AAGACCCCAGCAGACGACTC-39 and CYR61, 59- AGCT-
CTTCCTCTCCCGTTCA-39,5 9-ACAAGTGCCCACCTCAG-
GAA-39. Real-time PCR was carried out in a MX3000P
thermocycler (Stratagene) by using SYBR Green dye (ABgene,
Courtaboeuf Cedex; France). Normalization and quantification
were calculated according to the formula 2
DDCt. PCRs were
performed independently 3 times.
Human-chick ortholog identification : analysis of the
BLAST pipeline results
From the SAM analyses, there were 1252 (1176 non-redundant)
differentially expressed probes from the different conditions. The
bioinformatic goal was to identify the human ortholog of chicken
gene represented by the Affymetrix probes. A graph based, nearest
neighbour approach, Reciprocal Best Hit (RBH) [85], was chosen
in preference to multiple sequence alignments and phylogenetic
tree analyses, as performing those was not amenable to high-
throughput of the 1252 probes. Coupled to this was the fact that a
recent performance assessment of different ortholog prediction
methods found RBH performed well in comparison with other
methods [86]. An RBH approach uses BLAST to compare a
query sequence against another genome [85,87]. If the best gene
from the other genome best matches the original query sequence it
is termed a Reciprocal Best Hit. An RBH analysis was carried out
in three ways and the results combined to give the maximum
number of successful RBH human ortholog assignments.
Method 1: Affymetrix annotation data file, dated 3
rd March
2009 (Chicken.na28.annot.csv), was downloaded from Affymetrix
technical support website: http://www.affymetrix.com/support/
technical/annotationfilesmain.affx. 867 of the 1176 non-redun-
dant probes were annotated with a chicken protein accession by
Affymetrix. The chicken protein annotated in the Affymetrix file
was used as a query to search the human Refseq database of
proteins to assign orthologs by RBH. 745 of the 1176 non-
redundant probes were successfully assigned human orthologs.
Method 2: In this method, the accession nucleotide accessions in
the Chicken.na28.annot.csv file were collected and sequences used
to find the best chicken Refseq nucleotide. If the alignment was of
sufficient quality, .90% sequence identity and .=100bp
alignment length, then the protein sequence for the Refseq
nucleotide was used in a RBH analysis versus human proteins. 765
of the 1176 non-redundant probes were successfully assigned a
human ortholog using this method.
Method 3: A high-throughput method of assigning orthologs
through a Conditional Stepped Reciprocal Best approach
(CSRBH) (Herbert et al., manuscript under review) was used to
assign all probes a human ortholog. The nucleotide sequence was
first translated in six frames and BLAST searched against the
chicken and human Refseq protein databases. Whichever species
gave the most similar protein match, this protein used in a RBH
analysis to assign the ortholog. Therefore, if a chicken protein was
the most significant match to the nucleotide sequence, then that
chicken protein was used in a RBH analysis to assign a human
ortholog. Alternatively, if there was no chicken protein more
similar than a human protein, then the human protein was used in
the RBH analysis. The number of successful RBH human
orthologs assignments using this method was 719.
Combining results: By combining the three RBH methods of
ortholog assignments, 912 of the 1176 non-redundant probes were
successfully assigned human orthologs. Applying this to the
original list of 1252 redundant probes, 946 of them were
successfully assigned a human ortholog.
In silico EC and Non-EC gene enrichment prediction
To assign gene regulation in the CAM to specific cell types (EC
vs. Non-EC: stromal cells), we relied on a recent bioinformatic
approach. Preferentially expressed genes in cDNA libraries
isolated from endothelial cells (EC-ESTs, n=31114 ESTs) vs.
non-endothelial cells (Non-EC-EST, n=136622 ESTs) were
identified as described (Herbert et al. 2008 [32]). In their work,
a False Discovery Rate q-value [88,89s] of ,0.01 was used to
define endothelial differentially expressed genes. Although the
authors found highly endothelial specific genes applying this q-
value, in this work it was considered too stringent as endothelial
genes expressed at a low level could be missed because of low
coverage sequencing of cDNA libraries. Therefore, a less stringent
EC-enrichment fold-ratio method was used, which was calculated
by dividing the number of transcripts from the EC pool by the
number of transcripts from the non-EC pool (per million
transcripts). A two-fold upregulation threshold in endothelial cells
was applied and the q-value reported. Non-EC identity was
assigned to genes using the same criteria.
Bioinformatic tools
The bioinformatic analyses performed in this work can be done
locally on user data and can be downloaded from: http://www.
cbrg.ox.ac.uk/,jherbert/
Cloning of chick genes and in situ hybridization
Sense and antisense riboprobes (800–2000 bp 39UTR) were
prepared from cDNA of E7 CAM. Briefly, for SOX7, CYR61,
RAMP2 and DAG1 PCR products were amplified with indicated
chicken-specific primers and cloned into TOPO TA Cloning Kit
(with pCR 2.1-TOPO, Invitrogen). SOX7 (GgaAffx.20877.1.-
S1_at, XM_001234627; 997nt), F: TGCTTAGGTAAAG-
GATTTCG, R: GAAAATCATAGCCACGCTAC. CYR61
(GgaAffx.20877.1.S1_at XM_001234627; 1375nt), F: GAGAC-
CATGCGAATACAACT, R: TTCCAGTATTACAGGGGTTG.
RAMP2 (Gga.1941.1.S1_at NM_204099; 831nt). F: CCCAGA-
CAGGATTAAAGAGA, R: TAAACCTTTACTGCCCGATG.
DAG1 (GgaAffx.20323.1.S1_at NM_001097540; 1992 nt), F:
ATGACTGTTGGATGTGTCC, R: GGTGTTGTTGGTC-
CATTC. Plasmid carrying EPAS1 cDNA was kindly provided by
J. Favier (INSERM U977, France) [90]. In situ hybridization was
carried out essentially as described [91]. The genepaint database
([92]; http://www.genepaint.org) that provides digital in situ
hybridization images of sagittal sections of E14.5 mouse embryos
was queried for all genes indicated in Supplementary table S3.
Positive signal in capillaries of different organs was evidenced by
comparing to the expression pattern of known highly-specific
endothelial-specific genes CDH5 (VE-cadherin) or PECAM1
(CD31).
Comparison of CAM genes with other organs
Genes enriched in indicated human organs were retrieved from
the GNF SymAtlas v1.2.4, (http://symatlas.gnf.org/SymAtlas/
[61]). Transcripts with a three-fold enrichment over median
expression in 79 other tissues (MAS5 normalization) in lung
(n=1804), placenta (n=1320) whole brain (n=1462), whole
blood (n=1968), kidney (n=1121), pancreas (n=1154), liver
The CAM Transcriptome
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These gene lists were compared to high quality orthologs regulated
significantly during CAM development (n=946 probe sets) using a
web-based gene comparison tool (http://elegans.uky.edu/MA/
progs/Compare.html). Unique genes shared between the devel-
oping CAM and other organs are expressed as percentage of genes
enriched in the indicated organ.
Expression of EC-enriched genes in human cancers
Genes playing key roles during developmental angiogenesis are
often deregulated during pathological angiogenesis in solid tumors
[35]. To establish a link between CAM development genes and
tumor angiogenesis, we retrieved expression levels of all genes with
an EC-enrichement .2 (n=178) in four solid tumors (glioblas-
toma, lung adenocarcinoma, colon carcinoma and renal clear cell
carcinoma) using the Oncomine database ([93]; http://www.
oncomine.org). Oncomine centralizes expression profiles of over
3762 microarray experiments covering a broad panel of human
cancers and normal tissues and can be used to link expression of
novel genes with different grades of tumors, tumor sub-types and,
as has been recently shown for CD200 [94]. Expression levels for
selected genes were demonstrated for glioblastoma, one of the
most highly vascularized tumors. VEGF served as positive control
[95]. Expression was considered different to normal tissue, when
was P,.0001). Glioblastoma data originated from the study of Sun
et al. [96].
Functional analyses of PARVB knock down in human
endothelial cells
EC cell culture. hCMEC/D3 cells [73], (a kind gift of P.O.
Couraud, Institut Cochin, Paris) were maintained as described
[73]. Briefly, cells were plated onto type I collagen coated dishes
(rat tail collagen type I, 100mg/mL, BD Biosciences) in endothelial
basal medium (EBM2) (Lonza, Levallois-Perret cedex, France)
containing FBS and growth supplements (EGM2-MV) as
recommended by the manufacturers. The cultures were
maintained at 37uC in 5% CO2.
siRNAs and transfection
ON-TARGETplus siRNA against human PARVB (siPARVB)
(target sequence: G.G.A.A.G.A.A.C.C.U.G.G.U.G.G.C.C.A.U)
and ON-TARGETplus non-targeting siRNA (siCT) were de-
signed by Dharmacon (Thermofisher scientific, Courtaboeuf
cedex, France) and transfected into cells using Lipofectamine
RNAiMAX (Invitrogen, Cergy Pontoise cedex, France) according
to the manufacturers indications. Efficacy of PARVB knock down
was tested by semi-quantitative real-time PCR using the following
primers for PARVB: F: ATGGCGTGTACCTGGTTCTG; R:
AAGGCGAAGGACACATTGTGG.
EC migration, invasion, adhesion and proliferation
Migration and invasion of siCT and siPARVB-transfected
cells was evaluated using transwell chambers with a 8-mmp o r e
size polycarbonate membrane (Falcon, BD Bioscience, Le Pont
de Claix cedex, France), coated with type I collagen (100mg/ml)
or matrigel (20mg/100ml) respectively. The lower chambers
were filled with endothelial basal medium with or without
serum (0.5% and 0.1% for migration and invasion, respective-
ly). 5610
4 cells were seeded for migration assays and 1610
5
cells for invasion assays and incubated at 37uC for 3h
(migration), and 24h for invasion. Then, the non-migrated cells
on the upper side of filters were cleared with cotton swabs, and
the migrated cells were fixed with an acetic acid/MetOH
solution (10%/30%) and stained with Coomassie blue. The
number of migrated cells were counted by light microscopy (4
fields per inserts). Experiments were repeated three to four
times, with very reproducible results. All data are pooled and
analyzed using unpaired t-tests.
For adhesion assay and cell morphology studies, 3610
3 cells
were plated onto collagen-coated 96-wells plate, in EBM2 medium
plus BSA 1%. After 3 to 72h of adhesion, cells were rinsed three
times with PBS, fixed with an acetic acid/MetOH solution (10%/
30%) and stained with Coomassie blue. To quantify cell size at
3 hours of adhesion, total cell number was determined based on
coomassie staining under light microscope, total area occupied by
cells was determined by the imaging software (NIS-Elements AR
2.30 software; Nikon France), and mean surface per cell was
calculated (area/number of cells). The experiment was repeated
three times, and results pooled for statistical analysis (Mann-
Whitneys U-test).
For actin cytoskeleton staining, 3,5.10
4 hCMEC/D3 cells were
plated onto collagen-coated coverslides, in EBM2 medium plus
BSA 1%, and placed in 24 wells plate. Cell adhesion was allowed
for 3 hours at 37uC and 5% CO2. After 3 PBS washes, cells were
fixed with paraformaldehyde, permeabilized with PBS/Triton 1%
and saturated with BSA 5%. Rhodamine-phalloidin (Molecular
Probes) staining was performed to reveal actin cytoskeleton.
Images were acquired using a confocal microscope (Leica SP5).
For proliferation assay, 3610
3 hCMEC/D3 cells were seeded in
96-well plates in complete medium. After transfection with siARN
PARVB or siCT, cell proliferation was assessed by colorimetric
WST-1 assays (Roche, Neuilly sur Seine Cedex, France) at
indicated time points, according to manufacturers indications. The
results are expressed as raw values corrected for background
absorption. Five wells per day and condition were used and two
independent experiments pooled. Statistical analysis was done
using Mann-Whitneys U-test.
Tubulogenesis assay
25610
4 hCMEC/D3 were transfected with siRNAs for 72h,
mixed with matrigel on ice and then transferred into 24-well
culture dishes (350ml per well). EBM2 medium containing 0.1%
serum (hCMEC/D3) was then added and cells were incubated at
37uC. After 18–20h, photos were taken using a Leica light
microscope. Ten wells per condition were analyzed, and one
representative image is shown.
Supporting Information
Figure S1 Graphical representation of the SAM analysis. Each
SAM curve contains all the genes plotted by their observed scores
and expected scores. The red, green, and black dots represent up
regulated, down regulated, and insignificant genes respectively.
The upper and lower 45u degree lines indicate the D threshold
boundaries. Genes with D=0 would fall on the 45u line through
the origin. The number of significant genes, median number of
false positives, and false discovery rate are indicated at the upper
left corner of each plot sheet.
Found at: doi:10.1371/journal.pone.0007856.s001 (1.16 MB TIF)
Figure S2 Functional annotation clustering using DAVID. To
gain insight into biological processes enriched during CAM
development, we submitted significantly regulated genes to Gene
Ontology via DAVID. Biological processes, which were signifi-
cantly enriched in the submitted set of genes compared to the rest
of the genome, are indicated.
Found at: doi:10.1371/journal.pone.0007856.s002 (1.49 MB TIF)
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over expressed in human organs. A) Predicted EC-specific genes
enriched in indicated organs. B) Intersection of over expressed
genes shared between the CAM and the three indicated organs.
This gene set contained numerous known key regulators of
placenta and lung morphogenesis and vascularization.
Found at: doi:10.1371/journal.pone.0007856.s003 (1.55 MB
TIF)
Table S1 Full list of significantly regulated genes (.2-fold). The
Excel file contains up- and down regulated genes for each
developmental period compared: E5 vs. E7, E7 vs. E10 and E10 vs
E14.
Found at: doi:10.1371/journal.pone.0007856.s004 (0.23 MB
XLS)
Table S2 Ortholog identification process. This table contains
the ortholog screening process for all probes for which significant
changes have been found using the SAM analysis.
Found at: doi:10.1371/journal.pone.0007856.s005 (0.29 MB
XLS)
Table S3 Full list of putative human orthologs of CAM genes
with endothelial specificity (.2-fold enrichment). This table
contains 205 probe sets (178 unique genes) with significant
changes during indicated period of development. The 2-fold
enrichment indicates two times more transcripts found in the EC-
EST pool. 1: over expression in tumors; 21: under expression; 0:
no regulation; AMB: ambiguous regulation (over and under
expression found). Unique genes were identified using http://
elegans.uky.edu/MA/progs/Compare.html.
Found at: doi:10.1371/journal.pone.0007856.s006 (0.06 MB
XLS)
Table S4 Full list of putative human orthologs of CAM genes
with non-endothelial specificity (.2-fold enrichment). This table
contains 354 probe sets (297 unique genes) with significant changes
during indicated period of development. The 2-fold enrichment
indicates two times more transcripts found in the Non-EC-EST
pool. Unique genes were identified using http://elegans.uky.edu/
MA/progs/Compare.html.
Found at: doi:10.1371/journal.pone.0007856.s007 (0.08 MB
XLS)
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